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(57) ABSTRACT 
The present invention provides uricases and methods of their 
production and use in reducing the amount of uric acid in a 
subject. The present invention further provides methods 
employing a uricase of this invention in the treatment and/or 
prevention of hyperuricemia, gout, tumor lysis syndrome 
and/or hypertension in a subject. 
4 Claims, 3 Drawing Sheets 
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VARIANTS OF ANCESTRAL URICASES AND 
USES THEREOF 
RELATED APPLICATIONS 
2 
The present invention also provides cells that produce one 
or more uricase subunits and uricases of the present invention 
and methods of using those cells to produce uricases of the 
present invention. 
The present invention also provides pharmaceutical com-
positions comprising one or more uricases, nucleic acid mol-
ecules, vectors and/or cells of the present invention in a phar-
maceutically acceptable carrier. 
The present invention also provides a method ofreducing 
This application claims priority under35 U.S.C. § 119( e) to 
U.S. Provisional Application No. 61/322,094, filed Apr. 8, 
2010, the disclosure of which is incorporated herein by ref-
erence in its entirety. 
FIELD OF THE INVENTION 
The present invention relates to ancestral forms of mam-
malian uricases and uses thereof. 
10 
the amount of uric acid in a subject, comprising administering 
to the subject an effective amount of a uricase of the present 
invention. A method is also provided of reducing the amount 
of uric acid in a subject, comprising administering to the 
subject an effective amount of a composition ofthis invention 
comprising a uricase ofthis invention and a pharmaceutically 
15 acceptable carrier. 
BACKGROUND The present invention also provides a method of treating 
and/or preventing hyperuricemia, gout, tumor lysis syndrome 
and/or hypertension in a subject (e.g., a subject in need 
thereof), comprising administering to the subject an effective 
20 amount of a uricase of this invention and/or a nucleic acid 
Uric acid, a natural breakdown product of DNA, RNA and 
ATP, is considered to be one of the most important antioxi-
dants in blood plasma. Most mammals rely on uricase 
enzymes to maintain a uric acid plasma concentration of 
around 1-2 mg/di. Humans however, must rely on their kid-
neys to excrete most of the uric acid that is produced because 
the current human gene form is incapable of producing a 25 
functional uricase enzyme. 
Abnormally high uric acid levels have been associated with 
numerous disease states, including gout and tumor lysis syn-
drome. 
Recombinant uricases are administered forthe treatment of 30 
gout and as a prophylaxis against hyperuricemia caused by 
tumor lysis syndrome. The currently available uricase thera-
peutics, which comprise nonhuman uricase enzymes, are 
either ineffective or elicit undesirable immune responses 
(sometimes leading to anaphylactic shock or even death). See 35 
U.S. Pat. Nos. 6,783,965; 7,056,713; 7,723,089 and 7,811, 
800 and U.S. Patent Publication No. 2009/0169534. 
The present invention overcomes these problems by recon-
structing and resurrecting ancestral forms of the current 
40 
human uricase enzyme. Uricases of the present invention may 
be used therapeutically in humans to reduce uric acid levels 
without eliciting an undesirable immune response. 
molecule comprising a nucleotide sequence encoding one or 
more uricase subunits of this invention. Also provided herein 
is a method of treating and/or preventing hyperuricemia, 
gout, tumor lysis syndrome and/or hypertension in a subject 
(e.g., a subject in need thereof), comprising administering to 
the subject a composition of this invention, wherein said 
composition comprises a uricase and/or a nucleic acid mol-
ecule of this invention and a pharmaceutically acceptable 
earner. 
A uricase of the present invention may possess uricolytic 
activity that meets or exceeds the uricolytic activity of known 
uricases, such as Krystexxa ™ (Savient Pharmaceuticals, Inc., 
East Brunswick, N.J.) and Elitek® (SanofiAventia US, LLC, 
Bridgewater, N.J.). 
The foregoing and other objects and aspects of the present 
invention are explained in detail in the drawings and descrip-
tion set forth below. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1 is a graphical depiction of the phylogenetic tree used 
to reconstruct and resurrect ancestral forms of mammalian 
uricases. The phylogentic tree was constructed using 
Mr Bayes Version 3 .1 software (available at http://mrbayes.c-SUMMARY OF THE INVENTION 
The present invention provides uricases and uricase sub-
units, which represent ancestral forms of mammalian 
uricases or variants thereof. 
Uricases of the present invention can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to one or more of the 
respective amino acid sequences of SEQ ID NOs:l-9. 
Uricases of the present invention may be homomers or het-
eromers and may be conjugated to one or more oligomers, 
such as polyethylene glycol (PEG). 
45 sit.fsu.edu/download.php) using a general time reversible 
model with a proportion of invariable sites and a gamma-
shaped rate distributions across sites. The analysis comprised 
two runs of one million generations, with four chains each. 
One hundred thousand trees were sampled and the first one 
50 hundred trees were discarded as burnin. Branch lengths are 
not shown. 
FIG. 2 is a graphical representation of the results of the 
SDS-PAGE analysis described in Example 3. Lane A contains 
a Precision Plus Protein™ Kaleidoscope™ Marker (Bio-Rad 
55 Laboratories, Inc., Hercules, Calif.). Lane B contains a 
homotetrameric uricase having uricase subunits with the 
amino acid sequence of SEQ ID N0:3. Lane C contains a 
homotetrameric uricase having uricase subunits with the 
The present invention also provides nucleic acid molecules 
comprising one or more nucleotide sequences encoding one 60 
or more uricase subunits of the present invention and methods 
of using those nucleic acid molecules to produce a uricase of 
the present invention. 
The present invention also provides vectors comprising 
one or more nucleic acid molecules of the present invention 65 
and methods of using a vectors of this invention to produce a 
uricase of the present invention. 
amino acid sequence of SEQ ID N0:4. 
FIG. 3 is a chromatogram depicting the separation of 
uricase tetramers, octamers and aggregates described m 
Example 4. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention provides uricases and uricase sub-
units, which represent ancestral forms of mammalian 
US 8,940,861 B2 
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uricases or variants thereof. In addition, the present invention 
provides compositions and methods for metabolizing uric 
acid and/or reducing the amount of uric acid (e.g., a uric acid 
level) in a subject. 
Uricases of the present invention may possess uricolytic 
activity that meets or exceeds the uricolytic activity of known 
uricases. For example, a uricase of the present invention may 
possess uricolytic activity that is at least about 5%, I 0%, 15%, 
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 
70%, 75%, 80%, 85%, 90%, 95% 100%, 150%, 200%, 300%, 
400%, 500% or more higher than the uricolytic activity of one 
or more known uricases (e.g., a control uricase). 
Uricases of the present invention may possess thermody-
namic and/or kinetic stability that meets or exceeds that of 
known uricases. For example, a uricase of the present inven-
tion may possess thermodynamic and/or kinetic stability that 
is at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
95%, 100%, 150%, 200%, 300%, 400%, 500% or more 
higherthan that of one or more known uricases (e.g., a control 
uricase). 
A uricase of the present invention may be used to reduce 
the amount of uric acid in a subject and/or to prevent an 
increase in the amount of uric acid in a subject. In some 
embodiments, a uricase of the present invention can be used 
to reduce the amount of uric acid in a subject and/or to prevent 
an increase in the amount of uric acid in a subject while 
minimizing an undesirable immune response in the subject. 
In some embodiments, a uricase of the present invention can 
be administered in a therapeutically effective dose without 
eliciting any appreciable immunoreactivity to the uricase. 
DEFINITIONS 
Although the following terms are believed to be well 
understood by one of ordinary skill in the art, the following 
definitions are set forth to facilitate understanding of the 
presently disclosed subject matter. 
4 
example, as it is applied to a polynucleotide or polypeptide 
sequence of this invention, "consists essentially of' means 
that the polynucleotide or polypeptide sequence may consist 
of both the recited sequence (e.g., SEQ ID N0:2) and a total 
often or fewer (i.e., I, 2, 3, 4, 5, 6, 7, 8, 9 or 10) additional 
nucleotides or amino acids such that the function of the poly-
nucleotide or polypeptide sequence is not materially altered. 
The additional nucleotides or amino acids may be added to 
either end (or to both ends) of the recited sequence (i.e., the 
10 total number of additional nucleotides or amino acids 
includes the total number at both ends added together). The 
term "materially altered," as applied to polynucleotides of the 
invention, refers to an increase or decrease in ability to 
express the polynucleotide of at least about I 0%, 20%, 30%, 
15 40%, 50% or more as compared to the expression level of a 
polynucleotide consisting of the recited sequence. The term 
"materially altered," as applied to polypeptides of the inven-
tion, refers to an increase or decrease in activity (e.g., urico-
lytic activity) of at least about I 0%, 20%, 30%, 40%, 50% or 
20 more as compared to the activity of a polypeptide consisting 
of the recited sequence. 
As used herein, the term "gout" refers to a condition char-
acterized by an elevated uric acid level and the formation of 
uric acid crystals in one or more joints. Subjects with gout 
25 may experience a variety of symptoms, including, but not 
limited to, acute and/or chronic pain in one or more joints, 
swelling and fever. 
As used herein, the term "immunogenicity" refers to the 
induction of an immune response to an antigen following 
30 administration of the antigen (i.e., an immunogen such as 
unease. 
As used herein, the term "immunoreactivity" refers to both 
antigenicity and immunogenicity. In general, immunoreac-
tivity to a given antigen is assessed by monitoring/measuring 
35 I) the reaction of preexisting antibodies with the antigen, 2) 
the production of antibodies directed against the antigen and 
3) the rate at which the antigen is cleared following repeated 
administrations. 
All technical and scientific terms used herein, unless oth-
erwise defined below, are intended to have the same meaning 40 
as commonly understood by one of ordinary skill in the art. 
References to techniques employed herein are intended to 
refer to the techniques as commonly understood in the art, 
including variations on those techniques or substitutions of 
equivalent techniques that would be apparent to one of skill in 45 
the art. 
Non-limiting examples of an immune response as 
described herein include an antibody response (e.g., protec-
tive antibody response; neutralizing antibody response; anti-
body dependent cellular cytotoxicity), a cellular response 
(e.g., cytotoxic T cell response; T helper response; interleu-
kin-2 (IL-2) production; regulatory T cell (Treg) response; T 
helper I (Thi) response; T helper 2 (Th2) response; T helper 
17 (Thi 7) response), an innate response (e.g., dendritic cell, 
As used herein, the terms "a" or "an" or "the" may refer to 
one or more than one. For example, "a" cell can mean one cell 
or a plurality of cells. 
As used herein, the term "and/or" refers to and encom-
passes any and all possible combinations of one or more of the 
associated listed items, as well as the lack of combinations 
when interpreted in the alternative ("or"). 
As used herein, the term "about," when used in reference to 
a measurable value such as an amount of mass, dose, time, 
temperature, and the like, is meant to encompass variations of 
20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified 
amount. 
As used herein, the term "antigenicity" refers to the reac-
tion of an antibody with an antigen, such as uricase. 
natural killer cell, macrophage, polymorphonuclear cell ( neu-
trophil) ), and any combination thereof. The uricases of the 
present invention are designed to minimize or reduce any 
50 such immune response that may be deleterious or undesirable 
to elicit in a subject of this invention. 
As used herein, the term "isolated," as applied to nucleic 
acid molecules, proteins or protein fragments of the present 
invention, means that the nucleic acid or protein or protein 
55 fragment is sufficiently free of contaminants and/or cell com-
ponents with which nucleic acids or proteins normally occur. 
"Isolated" does not mean that the preparation is technically 
pure (homogeneous), but rather that it is sufficiently pure to 
provide the nucleic acid or protein or protein fragment in a 
60 form in which it can be used therapeutically. 
As used herein, the term "consists essentially of' (and 
grammatical variants thereof), as applied to the uricases, 
nucleic acid molecules, vectors, cells, compositions and 
methods of the present invention, means that the additional 
components and/or method steps may be added so long as the 65 
additional components and/or steps do not materially alter the 
basic and novel characteristics of the present invention. For 
An "isolated cell" as used herein is a cell or population of 
cells that have been removed from the environment in which 
the cell occurs naturally and/or altered or modified from the 
state in which the cell occurs in its natural environment. An 
isolated cell of this invention can be a cell, for example, in a 
cell culture. An isolated cell of this invention can also be a cell 
that can be in an animal and/or introduced into an animal and 
US 8,940,861 B2 
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wherein the cell has been altered or modified, e.g., by the 
introduction into the cell of a protein, nucleic acid molecule 
and/or vector of this invention. 
6 
TABLE 2-continued 
The terms "mutant," "mutation," and other grammatical 
variants encompass, at the amino acid sequence level of a 
uricase subunit of this invention, any substitution with any 
naturally occurring amino acid residue (Table 1 ), any substi-
tution with any non-naturally occurring amino acid residue 
(e.g., one or more of the non-naturally occurring amino acids 
listed in Table 2), any deletion, any insertion, and any com- 10 
bination thereof in a wild type amino acid sequence of a 
uricase subunit. These terms are also intended to encompass 
the incorporation of additional glycosylation sites into the 
uricase subunit of this invention, as well as modifications in 
the amino acid sequence of the uricase subunit that result in an 15 
alteration of the framework of the subunit and/or a tetramer/ 
octamer comprising the subunit. 
NON-NATURALLY OCCURRING 
AMINO ACID RESIDUE 
3-Arninoisobutyric acid 
2-Arninopimelic acid 
t-butylalanine 
Citrulline 
Cyclohexylalanine 
2,4-Diarninobutyric acid 
Desmosine 
2,2'-Diarninopimelic acid 
2,3-Diarninoproprionic acid 
N-Ethylglycine 
N-Ethylasparagine 
Homoarginine 
Homocysteine 
Homo serine 
Hydroxy lysine 
Alla-Hydroxy lysine 
3-Hydroxyproline 
4-Hydroxyproline 
Isodesmosine 
allo-Isoleucine 
ABBREVIATION 
bAib 
Apm 
t-BuA 
Cit 
Cha 
Dbu 
Des 
Dpm 
Dpr 
EtGly 
EtAsn 
hArg 
hCys 
hSer 
Hyl 
aHyl 
3Hyp 
4Hyp 
These mutations can be introduced at the nucleic acid level 
by altering or modifying the nucleotide sequence encoding 
the uricase subunit (e.g., to introduce into the nucleotide 20 
sequence a deletion, substitution, insertion, stop codon, mis-
sense mutation, nonsense mutation, etc.) according to well 
known methods to produce the desired mutation at the amino 
acid sequence level. The result of these mutations is the 
phenotype of enhanced urolytic activity and, optionally, 25 
enhanced thermodynamic and/or kinetic stability, as defined 
herein. The production and testing of such mutants to identify 
those with the phenotype ofthis invention can be carried out 
according to methods well known in the art and as described 
Methionine sulfoxide 
N-Methylglycine, sarcosine 
N-Methylisoleucine 
6-N-Methyllysine 
N-Methylvaline 
2-Naphthylalanine 
Norvaline 
Norleucine 
Ornithine 
4-Chlorophenylalanine 
2-Fluorophenylalanine 
3-Fluorophenylalanine 
4-Fluorophenylalanine 
Phenylglycine 
Beta-2-thienylalanine 
Ide 
alle 
MSO 
MeGly 
Melle 
MeLys 
Me Val 
2-Nal 
Nva 
Nle 
Orn 
Phe(4-Cl) 
Phe(2-F) 
Phe(3-F) 
Phe(4-F) 
Phg 
herein. 30 
TABLE 1 
ABBREVIATION 
NATURALLY OCCURRING 
AMINO ACID RESIDUE 
THREE-LETTER ONE-LETTER 
Alanine 
Arginine 
Asparagine 
Aspartic acid (Aspartate) 
Cysteine 
Glutaruine 
Glutaruic acid (Glutaruate) 
Glycine 
Histidine 
Isoleucine 
Leucine 
Lysine 
Methionine 
Phenylalanine 
Pro line 
Serine 
Threonine 
Tryptophan 
Tyrosine 
Valine 
CODE 
Ala 
Arg 
Asn 
Asp 
Cys 
Gln 
Glu 
Gly 
His 
Ile 
Leu 
Lys 
Met 
Phe 
Pro 
Ser 
Thr 
Trp 
Tyr 
Val 
TABLE2 
NON-NATURALLY OCCURRING 
AMINO ACID RESIDUE 
2-Arninoadipic acid 
3-Arninoadipic acid 
beta-Alanine, beta-Aminoproprionic acid 
2-Arninobutyric acid 
4-Arninobutyric acid, Piperidinic acid 
6-Aminocaproic acid 
2-Arninoheptanoic acid 
2-Arninoisobutyric acid 
CODE 
A 
R 
N 
D 
c 
Q 
E 
G 
H 
L 
K 
M 
F 
p 
s 
T 
w 
y 
v 
ABBREVIATION 
Aad 
bAad 
bAla 
Abu 
4Abu 
Acp 
Ahe 
Aib 
35 
Thi 
As used herein, the term "pharmaceutically acceptable" 
means that a compound or composition is suitable for admin-
istration to a subject to achieve the desired effect or treatment 
without unduly deleterious side effects in light of the severity 
of the disorder or disease and the necessity of the treatment. 
40 For example, a "pharmaceutically acceptable carrier" may be 
a material that is relatively non-toxic and innocuous to a 
subject at concentrations consistent with effective activity of 
the active ingredient so that any side effects ascribable to the 
carrier do not vitiate the beneficial effects of the active ingre-
45 dient (e.g., a non-toxic material that may be administered to a 
subject without causing any undesirable biological effects 
and without interfering with the uricolytic activity of a uricase 
of the present invention). 
The terms "prevent," "prevention," "preventing" and 
50 "attenuating" (and grammatical variations of each of those 
terms) refer to prevention and/or delay of the onset of a 
disease, disorder and/or a clinical signs and/or symptom(s) in 
a subject and/or a reduction or attenuation in the severity of 
the onset of the disease, disorder and/or clinical symptom(s) 
55 relative to what would occur in the absence of the methods of 
the invention. The prevention can be complete, e.g., the total 
absence of the disease, disorder and/or clinical signs and/or 
symptom(s). The prevention can also be partial, such that the 
occurrence of the disease, disorder and/or clinical signs and/ 
60 or symptom(s) in the subject and/or the severity of onset is 
less than what would occur in the absence of the present 
invention (i.e., attenuated). 
A "prevention effective" amount as used herein is an 
amount that is sufficient to prevent and/or delay the onset of a 
65 disease, disorder and/or clinical signs and/or symptoms in a 
subject and/ or to reduce and/ or delay the severity of the onset 
of a disease, disorder and/or clinical signs and/or symptoms 
US 8,940,861 B2 
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in a subject relative to what would occur in the absence of the 
methods of the invention. Those skilled in the art will appre-
ciate that the level of prevention need not be complete, as long 
as some benefit is provided to the subject. 
As used herein, the term "subject" (and grammatical vari-
ants thereof) refers to mammals, avians, reptiles, amphibians 
and fish. Mammalian subjects may include, but are not lim-
ited to, humans, non-human primates (e.g., gorillas, chimpan-
zees, gibbons, baboons, orangutans, macaques, monkeys, 
etc.), pigs, cows, horses, sheep, goats, dogs, cats, rats, mice, 
10 hamsters, guinea pigs and rabbits. In particular embodiments, 
the subject is a human. Avian subjects may include, but are not 
limited to, chickens, turkeys, ducks, geese, quail and pheas-
ant, and birds kept as pets (e.g., parakeets, parrots, macaws, 
cockatoos, and the like). In some embodiments, the subject is 
from an endangered species. In some embodiments, the sub- 15 
ject is a laboratory animal. Human subjects may include 
neonates, infants, juveniles, adults, and geriatric subjects. 
As used herein, the terms "effective amount" or "therapeu-
tically effective amount" or "treatment effective amount" 
refer to an amount that produces a biological effect in a 20 
subject, which can be an improvement and/or benefit to a 
subject. Alternatively stated, an "effective amount" or "thera-
peutically effective amount" or "treatment effective amount" 
is an amount that alleviates, reduces the severity of delays the 
onset of and/or inhibits the progress of at least one clinical 25 
symptom in the subject. Those skilled in the art will appreci-
ate that the improvement and/or benefit need not be complete 
or curative, so long as some benefit is provided to the subject. 
As used herein, the terms "treat," "treatment," and "treat-
ing" refer to reversing, alleviating, reducing the severity of, 
30 delaying the onset of, and/or inhibiting the progress of a 
disease or disorder as described herein, or at least one symp-
tom of a disease or disorder as described herein (e.g., allevi-
atingjoint pain or reducing the amount of uric acid present in 
one or more bodily fluids, such as plasma or whole blood). In 
some embodiments, treatment may be administered after one 35 
or more symptoms have developed. In other embodiments, 
treatment may be administered in the absence of symptoms. 
For example, treatment may be administered to a susceptible 
individual prior to the onset of symptoms (e.g., in light of a 
history of symptoms and/or in light of genetic or other sus- 40 
ceptibility factors). Treatment may also be continued after 
symptoms have resolved-for example, to prevent or delay 
their recurrence. 
8 
ments, the uricase represents an ancestral form of a human 
uricase or a variant (e.g., mutated form) thereof. 
Uricases of the present invention can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to one or more of the 
respective amino acid sequences of SEQ ID NOs:l-9. For 
example, uricases of the present invention can comprise, con-
sist essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to one or more of the 
respective amino acid sequences of SEQ ID NO: 1, SEQ ID 
N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ IDN0:5, SEQ ID 
N0:6, SEQ IDN0:7, SEQ ID N0:8 and SEQ ID N0:9. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID NO: 1. In some such embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
90% identical to the amino acid sequence of SEQ ID NO: 1. In 
some embodiments, the unease can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 95% identical to the amino 
acid sequence of SEQ ID NO: 1. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 is lysine. In some embodiments, the 
stability of the uricase may be enhanced by the presence of an 
Rat amino acid position 17 5, an Eat amino acid position 177, 
a Y at amino acid position 178, an L at amino acid position 
265, a G at amino acid position 273 and/or an Sor a Cat amino 
acid position 286 of the amino acid sequence of SEQ ID 
NO: 1. In some embodiments, the uricase can comprise, con-
sist essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is 100% identical to the 
amino acid sequence of SEQ ID NO: 1. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:2. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
96% identical to the amino acid sequence of SEQ ID N0:2. In 
As used herein, the term "tumor lysis syndrome" refers to 
complications resulting from massive spontaneous or chemo- 45 
theraphy-induced cytolysis. The destruction of tumor cells 
and the release of their intracellular contents into the extra-
cellular space leads to elevated levels of uric acid; which 
deposits in the tubules of the kidneys and lead to acute renal 
failure. 50 some embodiments, the amino acid at one or more of posi-
tions 96, 103, 146, 147, 192, 208, 220, 230 and 303 is lysine. 
In some embodiments, the stability of the uricase may be 
enhanced by the presence of an Rat amino acid position 175, 
an E at amino acid position 177, a Y at amino acid position 
As used herein, the terms "uricase" and "uric acid oxidase" 
are used interchangeably to refer to enzymes that catalyze the 
oxidation of uric acid. Unless otherwise indicated, "uricase" 
refers to a tetrameric or octameric uricase enzyme, and 
"uricase subunit" refers to a monomeric uricase protein mol-
ecule that may assemble with other monomeric uricase pro-
tein molecules to form a tetrameric or octameric unease 
enzyme. 
As used herein, the term "uricolytic activity" is expressed 
in International Units (IU), wherein an IU of uricase is 
defined as the amount of enzyme that consumes one micro-
mole of uric acid per minute. 
Uri cases 
U ricases of the present invention represent ancestral forms 
of mammalian uricases or variants thereof. In some embodi-
55 178, an L at amino acid position 265, a G at amino acid 
position 273 and/or an S or a C at amino acid position 286 of 
the amino acid sequence of SEQ ID N0:2. In some embodi-
ments, the uricase can comprise, consist essentially of or 
consist of one or more uricase subunits having an amino acid 
60 sequence that is 100% identical to the amino acid sequence of 
SEQIDN0:2. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
65 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:3. In some embodiments, the can comprise, 
US 8,940,861 B2 
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consist essentially of or consist of one or more uricase sub-
units having an amino acid sequence that is at least 95% 
identical to the amino acid sequence of SEQ ID N0:3. In 
some such embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least 98% identical to 
the amino acid sequence of SEQ ID N0:3. In some embodi-
ments, the amino acid at one or more of positions 96, 103, 
146, 147, 192, 208, 220, 230 and 303 of the amino acid 
sequence of SEQ ID N0:3 is lysine. In some embodiments, 10 
the uricase can comprise, consist essentially of or consist of 
one or more uricase subunits having an amino acid sequence 
that is 100% identical to the amino acid sequence of SEQ ID 
N0:3. 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:6. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
93% identical to the amino acid sequence of SEQ ID NO: 6. In 
some such embodiments, the can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 98% identical to the amino 
acid sequence of SEQ ID N0:6. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 
N0:6 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:4. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
94% identical to the amino acid sequence of SEQ ID N0:4. In 
some such embodiments, the can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 99% identical to the amino 
acid sequence of SEQ ID N0:4. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 
N0:4 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
acid position 175, an E at amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
at amino acid position 273 and/or an S or a C at amino acid 
position 286 of the amino acid sequence of SEQ ID N0:4. In 
some embodiments, the uricase can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is 100% identical to the amino acid 
sequence of SEQ ID N0:4. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:5. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
94% identical to the amino acid sequence of SEQ ID N0:5. In 
some such embodiments, the can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 99% identical to the amino 
acid sequence of SEQ ID N0:5. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 
N0:5 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
acid position 175, an E at amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
at amino acid position 273 and/or an S or a C at amino acid 
position 286 of the amino acid sequence of SEQ ID N0:5. In 
some embodiments, the can comprise, consist essentially of 
or consist of one or more uricase subunits having an amino 
acid sequence that is 100% identical to the amino acid 
sequence of SEQ ID N0:5. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
15 acid position 175, an Eat amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
at amino acid position 273 and/or an S or a C at amino acid 
position286 of the amino acid sequence of SEQ ID N0:6. In 
some embodiments, the can comprise, consist essentially of 
20 or consist of one or more uricase subunits having an amino 
acid sequence that is 100% identical to the amino acid 
sequence of SEQ ID N0:6. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
25 having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:7. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
30 uricase subunits having an amino acid sequence that is at least 
91 % identical to the amino acid sequence of SEQ ID N0:7. In 
some such embodiments, the can comprise, consist essen-
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 98% identical to the amino 
35 acid sequence of SEQ ID N0:7. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 
N0:7 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
40 acid position 175, an Eat amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
at amino acid position 273 and/or an S or a C at amino acid 
position 286 of the amino acid sequence of SEQ ID N0:7. In 
some embodiments, the uricase can comprise, consist essen-
45 tially of or consist of one or more uricase subunits having an 
amino acid sequence that is 100% identical to the amino acid 
sequence of SEQ ID N0:7. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
50 having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 
of SEQ ID N0:8. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
55 uricase subunits having an amino acid sequence that is at least 
90% identical to the amino acid sequence of SEQ ID NO: 8. In 
some such embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least 95% identical to 
60 the amino acid sequence of SEQ ID N0:8. In some embodi-
ments, the uricase can comprise, consist essentially of or 
consist of one or more uricase subunits having an amino acid 
sequence that is 100% identical to the amino acid sequence of 
SEQ ID NO: 8. That is, in some embodiments, the uricase can 
65 comprise, consist essentially of or consist of one or more 
uricase subunits having the amino acid sequence of Formula 
I (SEQ ID N0:8): 
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Formula I 
(SEQ ID NO, 8) 
MAHYHX 1X2X3X4 KNX5 EVEFVRTGYGKX6 X7VKVLHIQRDGKX8 HX9 
I KEV AT SVQLTLX10SKKDYLHGDNSDI I PTDTI KNTVHVLAKFKX11 
PWKX20X21X22KNGVX23HVHAFIHTPTGTHFCEVEQX24X25X26 
GPX27VIHSGIKDLKVLKTTQSGFEGFIX28DX29X30TTLPEVKDRCF 
MEISLPNIHX49 FNIDMSKX50GLINKEEVLLPLX51NPYGKITGTVKR 
KLSSX52L, 
whereinX 1 is Nor G; X2 is D, Nor H; X3 isY or L; X4 is K 
or T; X5 is Dor A; X6 is Dor E; X7 is Mor V; X8 is Y or H; X9 
is Sor I; X10 is S orN; X11 is G or E; X12 is S orT; X13 is A 
orG; X14 is MorV; X15 is C orG; X16 is E orK; X17 is Nor 
K; X18 is V or M; X19 is V orI; X20 is R or H; X21 is For L; 
X22 is E or G; X23 is Kor N; X24 is M, Lor K; X25 is R or K; 
X26 is S or G; X27 is P or Q; X28 is Kor R; X29 is Q, R or E; 
X30 is For Y; X31 is Q or K; X32 is Hor D; X33 is G, C or S; 
X34 is Dor A; X35 is E or K; X36 is Tor I; X37 is V or I; X38 
is R or L; X39 is I or L; X40 is L or M; X41 is E or K; X42 is F 
or S; X43 is G or D; X44 is E or K; X45 is Sor L; X46 is P orT; 
X47 is Y or C; X48 is E or A; X49 is Y or L; X50 is Mor G; X51 
is D, S or C and X52 is R or K. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 
N0:8 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
acid position 175, an E at amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
at amino acid position 273 and/or an S or a C at amino acid 
position 286 of the amino acid sequence of SEQ ID N0:8. 
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prise, consist essentially of or consist of four/eight identical 
uricase subunits having an amino acid sequence that is at least 
about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, 99% or 100% identical to one of the 
respective amino acid sequences of SEQ ID NO: 1, SEQ ID 
N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID 
N0:6, SEQ ID N0:7, SEQ ID N0:8 or SEQ ID N0:9. For 
example, the uricase can comprise, consist essentially of or 
consist of four/eight identical uricase subunits having an 
10 amino acid sequence that is at least about 50%, 55%, 60%, 
65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% 
or 100% identical to amino acid sequence of SEQ ID NO: 1, 
SEQ ID N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, 
SEQ ID N0:6, SEQ ID N0:7, SEQ ID N0:8 or SEQ ID N0:9 
15 (e.g., four/eight identical uricase subunits having an amino 
acid sequence that is at least 96% identical to the amino acid 
sequence of SEQ ID N0:2). In some embodiments, the 
uricase can comprise, consist essentially of or consist of 
four/eight identical uricase subunits having an amino acid 
20 sequence that is 100% identical to one of the respective amino 
acid sequences of SEQ ID NO: 1, SEQ ID N0:2, SEQ ID 
N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID 
N0:7, SEQ ID N0:8 or SEQ ID N0:9. For example, the 
uricase can comprise, consist essentially of or consist of 
25 four/eight identical uricase subunits having an amino acid 
sequence that is 100% identical to the amino acid sequence of 
SEQ ID NO: 1, SEQ ID N0:2, SEQ ID N0:3, SEQ ID N0:4, 
SEQ ID N0:5, SEQ ID N0:6,SEQ ID N0:7, SEQ ID NO: 8 
or SEQ ID N0:9 (e.g., each of the four/eight uricase subunits 
30 consists of the amino acid sequence of SEQ ID N0:2). 
Uricases of the present invention may be heterotetramers 
or heterooctamers, comprising at least two (e.g., 2, 3, 4, 5, 6, 
7 or 8) distinct uricase subunits. For example, the uricase can 
comprise, consist essentially of or consist of at least two 
35 previously known uricase subunits (e.g., at least one pig 
uricase subunit (SEQ ID NO:lO) and at least one baboon 
uricase subunit (SEQ ID NO: 11) ), at least one uricase subunit 
of the present invention and at least one previously known 
uricase subunit (e.g., at least one uricase subunit of the present 
40 invention and at least one pig uricase subunit (SEQ ID 
NO: 10)) or at least two distinct uricase subunits of the present 
invention. The heterotetramers/heterooctamers can be made 
up of any combination of uricase subunits and in any ratio. For 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
having an amino acid sequence that is at least about 50%, 
55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 
97%, 98%, 99% or 100% identical to the amino acid sequence 45 
of SEQ ID N0:9. In some embodiments, the uricase can 
comprise, consist essentially of or consist of one or more 
uricase subunits having an amino acid sequence that is at least 
98% identical to the amino acid sequence of SEQ ID N0:9. In 
some such embodiments, the can comprise, consist essen- 50 
tially of or consist of one or more uricase subunits having an 
amino acid sequence that is at least 99% identical to the amino 
acid sequence of SEQ ID N0:9. In some embodiments, the 
aminoacidatoneormoreofpositions96, 103, 146, 147, 192, 
208, 220, 230 and 303 of the amino acid sequence of SEQ ID 55 
N0:9 is lysine. In some embodiments, the stability of the 
uricase may be enhanced by the presence of an R at amino 
acid position 175, an E at amino acid position 177, a Y at 
amino acid position 178, an Lat amino acid position 265, a G 
example, a uricase of this invention can have one subunit 
comprising the amino acid sequence of SEQ ID N0:2, one 
subunit comprising the amino acid sequence of SEQ ID N0:3 
and two subunits comprising the amino acid sequence of a 
wild type (nonmodified) uricase subunit. 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterotetramer/heterooctamer 
wherein at least one of the uricase subunits has an amino acid 
sequence that is at least about 50%, 55%, 60%, 65% 70%, 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 
identical to one of the respective amino acid sequences of 
SEQ ID NOs:l-9. For example, the uricase can comprise, 
consist essentially of or consist of a heterotetramer/heterooc-
tamer wherein at least one of the uricase subunits has an 
amino acid sequence that is at least about 50%, 55%, 60%, 
65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% 
or 100% identical to one of the respective amino acid 
sequences of SEQ ID NO:l, SEQ ID N0:2, SEQ ID N0:3, 
SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, 
SEQ ID NO: 8 and SEQ ID N0:9 (e.g., at least one of the 
uricase subunits has an amino acid sequence that is at least 
at amino acid position 273 and/or an S or a C at amino acid 60 
position 286 of the amino acid sequence of SEQ ID N0:9. In 
some embodiments, the uricase can comprise, consist essen-
tially of or consist of one or more ukase subunits having an 
amino acid sequence that is 100% identical to the amino acid 
sequence of SEQ ID N0:9. 65 96% identical to the amino acid sequence of SEQ ID N0:2). 
U ricases of the present invention may be homotetramers or 
homooctamers. In some embodiments, the uricase can com-
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterotetramer/heterooctamer 
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wherein at least two of the uricase subunits has an amino acid 
sequence that is at least about 50%, 55%, 60%, 65% 70%, 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 
identical to one of the respective amino acid sequences of 
SEQ ID NOs:l-9. For example, the uricase can comprise, 5 
consist essentially of or consist of a heterotetramer/heterooc-
tamer wherein at least two of the uricase subunits has an 
amino acid sequence that is at least about 50%, 55%, 60%, 
65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% 
or 100% identical to one of the respective amino acid 10 
sequences of SEQ ID NO:l, SEQ ID N0:2, SEQ ID N0:3, 
SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, 
SEQ ID NO: 8 and SEQ ID N0:9 (e.g., at least one of the 
uricase subunits has an amino acid sequence that is at least 
96% identical to the amino acid sequence of SEQ ID N0:2 15 
and at least one other of the uricase subunits has an amino acid 
sequence that is at least 95% identical to the amino acid 
sequence of SEQ ID N0:3). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterotetramer/heterooctamer 20 
wherein at least three of the uricase subunits has an amino 
acid sequence that is at least about 50%, 55%, 60%, 65% 
70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 
100% identical to one of the respective amino acid sequences 
of SEQ ID NOs:l-9. For example, the uricase can comprise, 25 
consist essentially of or consist of a heterotetramer/heterooc-
tamer wherein at least three of the uricase subunits has an 
amino acid sequence that is at least about 50%, 55%, 60%, 
65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% 
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subunits has an amino acid sequence that is at least about 
50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, 99% or 100% identical to one of the respec-
tive amino acid sequences of SEQ ID NO:l, SEQ ID N0:2, 
SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, 
SEQ ID N0:7, SEQ ID NO: 8 and SEQ ID NO: 9 (e.g., at least 
three of the uricase subunits has an amino acid sequence that 
is at least 96% identical to the amino acid sequence of SEQ ID 
N0:2 and at least two other of the uricase subunits has an 
amino acid sequence that is at least 95% identical to the amino 
acid sequence of SEQ ID N0:3). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterooctamer wherein at least 
six of the uricase subunits has an amino acid sequence that is 
at least about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one of 
the respective amino acid sequences of SEQ ID NO: 1, SEQ 
ID N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ 
ID N0:6, SEQ ID N0:7, SEQ ID N0:8 or SEQ ID N0:9. For 
example, the uricase can comprise, consist essentially of or 
consist of a heterooctamer wherein at least six of the uricase 
subunits has an amino acid sequence that is at least about 
50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, 99% or 100% identical to one of the respec-
tive amino acid sequences of SEQ ID NO:l, SEQ ID N0:2, 
SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, 
SEQ ID N0:7, SEQ ID NO: 8 and SEQ ID NO: 9 (e.g., at least 
three of the uricase subunits has an amino acid sequence that 
is at least 96% identical to the amino acid sequence of SEQ ID 
30 N0:2 and at least three other of the uricase subunits has an or 100% identical to one of the respective amino acid 
sequences of SEQ ID NO:l, SEQ ID N0:2, SEQ ID N0:3, 
SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, 
SEQ ID NO: 8 and SEQ ID N0:9 (e.g., at least two of the 
uricase subunits has an amino acid sequence that is at least 
96% identical to the amino acid sequence of SEQ ID N0:2 35 
and at least one other of the uricase subunits has an amino acid 
sequence that is at least 95% identical to the amino acid 
sequence of SEQ ID N0:3). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterotetramer/heterooctamer 40 
wherein at least four of the uricase subunits has an amino acid 
sequence that is at least about 50%, 55%, 60%, 65% 70%, 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 
identical to one of the respective amino acid sequences of 
SEQ ID NOs:l-9. For example, the uricase can comprise, 45 
consist essentially of or consist of a heterotetramer/heterooc-
tamer wherein at least four of the uricase subunits has an 
amino acid sequence that is at least about 50%, 55%, 60%, 
65% 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% 
amino acid sequence that is at least 95% identical to the amino 
acid sequence of SEQ ID N0:3). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterooctamer wherein at least 
seven of the uricase subunits has an amino acid sequence that 
is at least about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one of 
the respective amino acid sequences of SEQ ID NOs: 1-9. For 
example, the uricase can comprise, consist essentially of or 
consist of a heterooctamer wherein at least seven of the 
uricase subunits has an amino acid sequence that is at least 
about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, 99% or 100% identical to one of the 
respective amino acid sequences of SEQ ID NO: 1, SEQ ID 
N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID 
N0:6, SEQ ID N0:7, SEQ ID NO: 8 and SEQ ID N0:9 (e.g., 
at least three of the uricase subunits has an amino acid 
sequence that is at least 96% identical to the amino acid 
sequence of SEQ ID N0:2, at least two other of the uricase 
50 subunits has an amino acid sequence that is at least 95% 
identical to the amino acid sequence of SEQ ID N0:3 and at 
least two other of the uricase subunits has an amino acid 
sequence that is at least 94% identical to the amino acid 
or 100% identical to one of the respective amino acid 
sequences of SEQ ID NO:l, SEQ ID N0:2, SEQ ID N0:3, 
SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, SEQ ID N0:7, 
SEQ ID NO: 8 and SEQ ID N0:9 (e.g., three of the subunits 
have an amino acid sequence that is at least 96% identical to 
the amino acid sequence of SEQ ID N0:2 and one of the 55 
subunits has an amino acid sequence that is at least 95% 
identical to the amino acid sequence of SEQ ID N0:3). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterooctamer wherein at least 
five of the uricase subunits has an amino acid sequence that is 
at least about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to one of 
the respective amino acid sequences of SEQ ID NO: 1, SEQ 
ID N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ 
ID N0:6, SEQ ID N0:7, SEQ ID N0:8 or SEQ ID N0:9. For 
example, the uricase can comprise, consist essentially of or 
consist of a heterooctamer wherein at least five of the uricase 
sequence of SEQ ID N0:4). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of a heterooctamer wherein each of 
the eight uricase subunits has an amino acid sequence that is 
at least about 50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one of 
60 the respective amino acid sequences of SEQ ID NO: 1, SEQ 
ID N0:2, SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ 
ID N0:6, SEQ ID N0:7, SEQ ID N0:8 or SEQ ID N0:9. For 
example, the uricase can comprise, consist essentially of or 
consist of a heterooctamer wherein each of the eight uricase 
65 subunits has an amino acid sequence that is at least about 
50%, 55%, 60%, 65% 70%, 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, 99% or 100% identical to one of the respec-
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tive amino acid sequences of SEQ ID NO:l, SEQ ID N0:2, 
SEQ ID N0:3, SEQ ID N0:4, SEQ ID N0:5, SEQ ID N0:6, 
SEQ ID N0:7, SEQ ID NO: 8 and SEQ ID N0:9 (e.g., three 
of the uricase subunits has an amino acid sequence that is at 
least 96% identical to the amino acid sequence of SEQ ID 
N0:2, two other of the uricase subunits has an amino acid 
sequence that is at least 95% identical to the amino acid 
sequence of SEQ ID N0:3, two other of the uricase subunits 
has an amino acid sequence that is at least 94 % identical to the 
amino acid sequence of SEQ ID N0:4 and one other of the 10 
uricase subunits has an amino acid sequence that is at least 
94% identical to the amino acid sequence of SEQ ID N0:5). 
In some embodiments, the uricase can comprise, consist 
essentially of or consist of one or more uricase subunits 
selected from the group consisting of: 15 
a) a uricase subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDNO:l; 
b) a unease subunit having an amino acid sequence that is 
at least 96% identical to the amino acid sequence of SEQ 20 
IDN0:2; 
c) a unease subunit having an amino acid sequence that is 
at least 95% identical to the amino acid sequence of SEQ 
ID N0:3; 
d) a unease subunit having an amino acid sequence that is 25 
at least 94% identical to the amino acid sequence of SEQ 
ID N0:4; 
e) a unease subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
ID N0:5; 30 
f) a unease subunit having an amino acid sequence that is at 
least 93% identical to the amino acid sequence of SEQ 
IDN0:6; 
g) a unease subunit having an amino acid sequence that is 
at least 91 % identical to the amino acid sequence of SEQ 35 
IDN0:7; 
h) a unease subunit havng an amino acid sequence that is at 
least 90% identical to the amino acid sequence of SEQ 
IDN0:8; 
i) a unease subunit having an amino acid sequence that is at 40 
least 98% identical to the amino acid sequence of SEQ 
IDN0:9; and 
j) any combination of the subunits a. through i. above. 
In some embodiments, the unease is a tetramer comprising, 
consisting essentially of or consisting of one, two, three or 45 
four distinct subunits selected from the group consisting of: 
a) a unease subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDNO:l; 
b) a unease subunit having an amino acid sequence that is 50 
at least 96% identical to the amino acid sequence of SEQ 
IDN0:2; 
c) a unease subunit having an amino acid sequence that is 
16 
h) a uricase subunit havng an amino acid sequence that is at 
least 90% identical to the amino acid sequence of SEQ 
IDN0:8; and 
i) a uricase subunit having an amino acid sequence that is at 
least 98% identical to the amino acid sequence of SEQ 
IDN0:9. 
In some embodiments, the uricase is an octamer compris-
ing, consisting essentially of or consisting of one, two, three, 
four, five, six, seven or eight distinct subunits selected from 
the group consisting of: 
a) a uricase subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDNO:l; 
b) a uricase subunit having an amino acid sequence that is 
at least 96% identical to the amino acid sequence of SEQ 
IDN0:2; 
c) a uricase subunit having an amino acid sequence that is 
at least 95% identical to the amino acid sequence of SEQ 
ID N0:3; 
d) a uricase subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
ID N0:4; 
e) a uricase subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
IDN0:5; 
f) a uricase subunit having an amino acid sequence that is 
at least 93% identical to the amino acid sequence of SEQ 
IDN0:6; 
g) a uricase subunit having an amino acid sequence that is 
at least 91 % identical to the amino acid sequence of SEQ 
IDN0:7; 
h) a uricase subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDN0:8; and 
i) a uricase subunit having an amino acid sequence that is at 
least 98% identical to the amino acid sequence of SEQ 
IDN0:9. 
Conjugated Uricases 
Uricases of the present invention may be conjugated to one 
or more oligomers. That is, one or more oligomers may be 
conjugated to the uricase subunits that make up a uricase of 
the present invention. In some embodiments, each of the 
uricase subunits that make up the uricase is conjugated to at 
least one oligomer. 
Any suitable oligomer can be conjugated to uricases of the 
present invention, including, but limited to, poly-dispersed 
oligomers (such as those described in U.S. Pat. Nos. 4,179, 
337; 5,567,422; 5,359,030; 5,438,040; 5,681,811 and 6,309, 
633) and non-poly-dispersed oligomers (such as those 
described in U.S. patent application Ser. Nos. 09/873, 731; 
09/873,797 and 09/873,899). 
In some embodiments, the oligomer comprises, consists at least 95% identical to the amino acid sequence of SEQ 
ID N0:3; 
d) a unease subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
ID N0:4; 
55 essentially of or consists of a hydrophilic moiety, such as a 
polyalkylene glycol (including, but not limited to, polypro-
pylene glycol, polybutylene glycol and PEG moieties) or a 
polyoxyethylenated polyol. 
e) a unease subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
IDN0:5; 
f) a unease subunit having an amino acid sequence that is at 
least 93% identical to the amino acid sequence of SEQ 
IDN0:6; 
g) a unease subunit having an amino acid sequence that is 
at least 91 % identical to the amino acid sequence of SEQ 
IDN0:7; 
In some embodiments, the oligomer comprises, consists 
60 essentially of or consists of a lipophilic moiety, such as a 
saturated, linear alkyl moiety (including, but not limited to, 
methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, 
nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentade-
cyl, hexadecyl, octadecyl, nonadecyl and eicosyl moieties) a 
65 saturated, branched alkyl moiety (including, but not limited 
to, isopropyl, sec-butyl, tert-butyl, 2-methylbutyl, tert-pentyl, 
2-methyl-pentyl, 3-methylpentyl, 2-ethylhexyl and 2-propy-
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lpentyl moieties), an unsaturated alkyl moieties derived from 
the aforementioned saturated alkyl moieties (including, but 
not limited to, vinyl, ally!, 1-butenyl, 2-butenyl, ethynyl, 
1-propynyl and 2-propynyl moieties), a natural or synthetic 
unsaturated fatty acid moiety (including, but not limited to, 
lauroleate, myristoleate, palmitoleate, oleate, elaidate, eru-
cate, linoleate, linolenate, arachidonate, eicosapentaentoate 
and docosahexaenoate moieties) or a natural or synthetic 
saturated fatty acid moiety (including, but not limited to, 
acetate, caproate, caprylate, caprate, laurate, arachidate, 10 
behenate, lignocerate and cerotate moieties). 
The oligomer can comprise one or more other moieties, 
including, but not limited to, additional hydrophilic moieties, 
lipophilic moieties, bonding moieties (including, but not lim-
ited to, ester, thio-ester, ether, carbamate, thio-carbamate, 15 
carbonate, thio-carbonate, amide and urea moieties and cova-
lent bonds), spacer moieties (including, but not limited to, 
sugar, cholesterol and glycerine moieties), linker moieties 
(including, but not limited to, alkyl and fatty acid moieties as 
described above), and terminating moieties (including, but 20 
not limited to, alkyl, alkoxy, sugar, cholesterol, alcohol and 
fatty acid moieties). The various moieties in the oligomer can 
be covalently coupled to one another by either hydrolyzable 
or non-hydrolyzable bonds. 
In accordance with some embodiments of the present 25 
invention, the uricase-oligomer conjugate comprises the 
structure of Formula II: 
URICASE-BLw-Sx-R-Sy-R'-Sz-T (Formula 11) 
wherein URICASE represents a uricase of the present inven- 30 
tion, B represents a bonding moiety, L represents a linker 
moiety, S represents a spacer moiety, R represents a lipophilic 
moiety or a hydrophilic moiety, R' represents a lipophilic 
moiety or a hydrophilic moiety and T represents a terminating 
moiety, wherein R and R' cannot simultaneously represent a 35 
lipophilic moiety, wherein R and R' cannot simultaneously 
represent a hydrophilic moiety, and wherein w, x, y and z are 
individually 0 or 1. 
In some embodiments, a plurality of oligomers may be 
conjugated to a unease of the present invention. In such 40 
embodiments, the plurality of oligomers may comprise one or 
more oligomer types. That is, each of the oligomers, in the 
plurality can be the same or the plurality may comprise at 
least two distinct oligomers (e.g., a first oligomer having a 
lipophilic moiety but no hydrophilic moiety and a second 45 
oligomer having a hydrophilic moiety but no lipophilic moi-
ety). 
In some embodiments, the conjugation of one or more 
oligomers to a unease of the present invention reduces the 
antigenicity of the unease and/or prolongs the circulating 50 
half-life of the unease. For example, conjugating one or more 
PEG moieties to a unease of the present invention may reduce 
the antigenicty of the unease by at least about 5%, 10, 20%, 
30, 40%, 50%, 60%, 70%, 80%, 90% or more as compared to 
an unconjugated version of the same unease. Likewise, con- 55 
ju gating one or more PEG moieties to a unease of the present 
invention may prolong the circulating half-life of the unease 
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tion. In some embodiments, the isolated nucleic acid mol-
ecule comprises, consists essentially or of consists of a 
nucleic acid sequence that encodes one or more unease sub-
units selected from the group consisting of: 
a) a uricase subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDNO:l; 
b) a uricase subunit having an amino acid sequence that is 
at least 96% identical to the amino acid sequence of SEQ 
IDN0:2; 
c) a uricase subunit having an amino acid sequence that is 
at least 95% identical to the amino acid sequence of SEQ 
ID N0:3; 
d) a uricase subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
ID N0:4; 
e) a uricase subunit having an amino acid sequence that is 
at least 94% identical to the amino acid sequence of SEQ 
IDN0:5; 
f) a uricase subunit having an amino acid sequence that is 
at least 93% identical to the amino acid sequence of SEQ 
IDN0:6; 
g) a uricase subunit having an amino acid sequence that is 
at least 91 % identical to the amino acid sequence of SEQ 
IDN0:7; 
h) a uricase subunit having an amino acid sequence that is 
at least 90% identical to the amino acid sequence of SEQ 
IDN0:8; 
i) a uricase subunit having an amino acid sequence that is at 
least 98% identical to the amino acid sequence of SEQ 
IDN0:9; and 
j) any combination of the subunits a. through i. above. 
Also provided herein is a vector comprising a nucleic acid 
molecule encoding one or more uricase subunits of this inven-
tion and/or fragments thereof. The vector can be an expres-
sion vector which contains all of the genetic components 
required for expression of the nucleic acid in cells into which 
the vector has been introduced, as are well known in the art. 
The expression vector can be a commercial expression vector 
or it can be constructed in the laboratory according to stan-
dard molecular biology protocols. The expression vector can 
comprise viral nucleic acid including, but not limited to, 
poxvirus, vaccinia virus, adenovirus, retrovirus, alphavirus 
and/or adeno-associated virus nucleic acid. The nucleic acid 
molecule or vector of this invention can also be in a Ii po some 
or a delivery vehicle, which can be taken up by a cell via 
receptor-mediated or other type of endocytosis. 
The nucleic acid molecule of this invention can be in a cell, 
which can be a cell expressing the nucleic acid whereby a 
uricase subunit and/or fragment thereof of this invention is 
produced in the cell (e.g., a host cell). In addition, the vector 
of this invention can be in a cell, which can be a cell express-
ing the nucleic acid of the vector whereby a uricase subunit 
and/or fragment thereof of this invention is produced in the 
cell. It is also contemplated that the nucleic acids and/or 
vectors of this invention can be present in a host organism 
(e.g., a transgenic organism), which expresses the nucleic 
acids of this invention and produces the uricase subunits 
by at least about 5%, 10, 20%, 30, 40%, 50%, 60%, 70%, 
80%, 90%, 100%, 150%, 200% or more as compared to an 
unconjugated version of the same unease. 60 and/or fragments of this invention. 
Nucleic Acid Molecules Encoding Uricases of the 
Present Invention 
The present invention further provides an isolated nucleic 
acid molecule comprising a nucleotide sequence encoding 
one or more unease subunits or fragment thereof of this inven-
In some embodiments, the nucleic acid molecules encod-
ing the polypeptides and/or fragments of this invention can be 
part of a recombinant nucleic acid construct comprising any 
combination of restriction sites and/or functional elements as 
65 are well known in the art that facilitate molecular cloning and 
other recombinant nucleic acid manipulations. Thus, the 
present invention further provides a recombinant nucleic acid 
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construct comprising a nucleic acid molecule encoding a 
polypeptide and/or fragment of this invention. 
The nucleic acid molecule encoding the polypeptide and/or 
fragment of this invention can be any nucleic acid molecule 
that functionally encodes the polypeptides and/or fragments 
20 
Pharmaceutical Compositions/Methods 
of this invention. To functionally encode the polypeptides 
and/or fragments (i.e., allow the nucleic acids to be 
expressed), the nucleic acid ofthis invention can include, for 
example, expression control sequences, such as an origin of 
replication, a promoter, an enhancer and necessary informa- 10 
tion processing sites, such as ribosome binding sites, RNA 
splice sites, polyadenylation sites and transcriptional termi-
nator sequences. 
Uricases, uricase subunits, nucleic acid molecules, vectors 
and cells of the present invention can be administered to a 
subject to reduce the amount of uric acid in the subject and/or 
prevent an increase in the amount of uric acid in the subject. 
Uricases, uricase subunits, nucleic acid molecules, vectors 
and cells of the present invention can be used for medical, 
veterinary and/or research purposes (e.g., they can be tested in 
uricase-deficient animals, such as Uox+1- or Vox-1- mice 
(See, e.g., Kelly et al., J. Am. Soc. Nephrol. 12:1001-1009 
(2001)). 
Uricases, nucleic acid molecules, vectors and cells of the 
present invention (and compositions comprising one or more 
Non-limiting examples of expression control sequences 
that can be present in a nucleic acid molecule of this invention 
include promoters derived from metallothionine genes, actin 
genes, immunoglobulin genes, CMV, SV40, adenovirus, 
bovine papilloma virus, etc. A nucleic acid molecule encod-
ing a selected polypeptide and/or fragment can readily be 
determined based upon the genetic code for the amino acid 
sequence of the selected polypeptide and/or fragment and 
many nucleic acids will encode any selected polypeptide 
and/or fragment. Modifications in the nucleic acid sequence 
encoding the polypeptide and/or fragment are also contem-
plated. Modifications that can be useful are modifications to 
the sequences controlling expression of the polypeptide and/ 
or fragment to make production of the polypeptide and/or 
fragment inducible or repressible as controlled by the appro-
priate inducer or repressor. Such methods are standard in the 
art. The nucleic acid molecule and/or vector of this invention 
can be generated by means standard in the art, such as by 
recombinant nucleic acid techniques and/or by synthetic 
nucleic acid synthesis or in vitro enzymatic synthesis. 
The nucleic acids and/or vectors of this invention can be 
transferred into a host cell (e.g., a prokaryotic or eukaryotic 
cell) by well known methods, which vary depending on the 
type of cell host. For example, calcium chloride transfection 
15 uricases of the present invention, one or more nucleic acid 
molecules of the present invention, one or more vectors of the 
present invention and/or one or more cells of the present 
invention) can be used therapeutically to treat and/or prevent 
various disorders, including, but not limited to, hyperurice-
20 mia, gout, tumor lysis syndrome and hypertension. In some 
embodiments, uricases, nucleic acid molecules, vectors and 
cells of the present invention (and compositions comprising 
one or more uricases of the present invention, one or more 
nucleic acid molecules of the present invention, one or more 
25 vectors of the present invention and/or one or more cells of the 
present invention) may be used as a prophylaxis against hype-
ruricemia caused by tumor lysis syndrome in the treatment of 
cancer. For example, administration ofuricases, nucleic acid 
molecules, vectors and cells of the present invention (and 
30 compositions comprising one or more uricases of the present 
invention, one or more nucleic acid molecules of the present 
invention, one or more vectors of the present invention and/or 
one or more cells of the present invention) to a subject in need 
thereof (e.g., a subject with cancer and/or a subject undergo-
35 ing treatment for cancer) can reduce the risk of developing 
hyperuricemia as well as prevent or delay the onset of hype-
runcemia. 
is commonly used for prokaryotic cells, whereas calcium 
phosphate treatment, transduction, cationic lipid treatment 40 
and/or electroporation can be used for other cell hosts. 
Uricases, nucleic acid molecules, vectors and cells of the 
present invention (and compositions comprising one or more 
uricases of the present invention, one or more nucleic acid 
molecules of the present invention, one or more vectors of the 
Uricase-Producing Cells 
Cells that produce one or more uricase subunits and/or 
uricases of the present invention are also provided. Such cells 
may comprise one or more nucleic acid molecules and/or 
vectors of the present invention. Any suitable cell known in 
the art may be used, including, but not limited to, bacterial 
cells (e.g., Escherichia coli and Bacillus subtilis), yeast cells 
(e.g., Saccharamyces cerevisiae), filamentous fungi (e.g., 
Aspergillus), plant cells, animal cells and insect cells. 
Cells of the present invention can be maintained in culture 
under conditions suitable for the expression of one or more 
uricase subunits of the present invention and/or the formation 
of one or more uricases of the present invention. Those skilled 
in the art will appreciate that the conditions suitable for the 
expression of uricase subunits and/or the formation of 
uricases may vary depending on the identity of the cells 
comprising the nucleic acid molecule(s) and/or vector(s) of 
the present invention, the nucleic acid molecule(s) and/or 
vector(s) being expressed, the uricase subunit(s) being 
expressed, etc. Such conditions for culturing cells of this 
invention are well known in the art. 
Uricases of the present invention can be extracted and 
purified from uricase-producing cells of the present invention 
using any suitable method known in the art. 
present invention and/or one or more cells of the present 
invention) can be used alone or in combination with other 
therapeutic agents/compositions, including, but not limited 
45 to, allopurinol, known uricases (e.g., Krystexxa™ (Savient 
Pharmaceuticals, Inc., East Brunswick, N.J.) and/or Elitek® 
(Sanofi Aventia US, LLC, Bridgewater, N.J.)), uricosuric 
agents (e.g., probeecid, benzbromarone and/or sulfinpyra-
zone), and anti-inflarmnatory agents (e.g., nonsteroidal anti-
50 inflammatory drugs and/or glucocorticoids). 
In some embodiments, compositions comprising one or 
more (unconjugated or conjugated) uricases of the present 
invention, one or more nucleic acid molecules of the present 
invention, one or more vectors of the present invention and/or 
55 one or more cells of the present invention are provided. Such 
compositions may comprise additional medicinal agents, sta-
bilizing agents, buffers, carriers, adjuvants, diluents, etc. 
Compositions of the present invention may comprise any 
suitable pharmaceutically acceptable carrier, including, but 
60 not limited to, phosphate buffered saline and isotonic saline 
solution. Other examples of pharmaceutically acceptable car-
riers may be found, for example, in PHARMACEUTICAL SCIENCES 
(18th Ed., Mack Publishing Co. (1990)) or REMINGTON: THE 
SCIENCE AND PRACTICE OF PHARMAcY (20th Ed., Lippincott Will-
65 iams & Wilkins (2000)). 
Compositions of the present invention may comprise any 
suitable diluents(s) or excipient(s ), including, but not limited 
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to, those set forth in REMINGTON: THE SCIENCE AND PRACTICE OF 
PHARMACY (20th Ed., Lippincott Williams & Wilkins (2000)) 
and HANDBOOK OF PHARMACEUTICAL ExcIPIENTS (6th Ed., Ameri-
can Pharmaceutical Association (2009)). 
Compositions of the present invention may be formulated 
so as to be suitable for administration via any known method, 
including, but not limited to, oral administration, parenteral 
administration (including, but not limited to, subcutaneous, 
intravenous, intramuscular, intrathecal and interperitoneal 
injection) and topical administration (including, but not lim-
ited to, transdermal administration, intranasal administration, 
vaginal administration, rectal administration and inhalational 
administration). In some embodiments, the composition is 
formulated for intravenous injection. 
For oral administration, compositions of the present inven-
tion may be formulated into solid or liquid preparations (e.g., 
capsules, pills, tablets, troches, lozenges, melts, powders, 
solutions, suspensions or emulsions) according to methods 
known in the art for the manufacture of pharmaceutical com-
positions. 
For parenteral administration, compositions of the present 
invention may be formulated for subcutaneous, intravenous, 
intramuscular, intrathecal or interperitoneal injection accord-
ing to methods known in the art for the manufacture of phar-
maceutical compositions. For example, uricases of the 
present invention may be formulated into injectable dosages 
with a pharmaceutically acceptable carrier, such as sterile 
saline or peanut oil. Injectable compositions of the present 
invention may typically contain about 0.5% to about 25% by 
weight of the uricase(s) of the present invention. A non-ionic 
surfactant may be included in a range of about 5% to about 
15% by weight to minimize or eliminate irritation at the site of 
injection. Preservatives and buffers may also be included. 
For topical administration, compositions of the present 
invention may be formulated into a topical cream/lotion/gel 
or a transdermal patch according to methods known in the art 
for the manufacture of pharmaceutical compositions. Trans-
dermal patches may be formulated to provide continuous, 
discontinuous and/or on-demand infusion of uricases of the 
present invention in controlled amounts. 
Methods of reducing the amount of uric acid and/or pre-
venting an increase in the amount of uric acid ina subject can 
comprise, consist essentially of or consist of administering to 
the subject an effective amount of one or more (unconjugated 
or conjugated) uricases of the present invention, one or more 
nucleic acid molecules of the present invention, one or more 
vectors of the present invention and/or one or more cells of the 
present invention. 
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cutaneous, intravenous, intramuscular, intrathecal injection 
and interperitoneal injection) and topical administration (in-
cluding, but not limited to, transdermal administration, intra-
nasal administration, vaginal administration, rectal adminis-
tration and inhalational administration). In some 
embodiments, the uricase(s), nucleic acid molecule(s), 
vector(s) and/or cell(s) are administered via intravenous 
injection. Uricases, nucleic acid molecules, vectors and cells 
of the present invention can be administered using any con-
10 ventional dosage unit/form, 
One of skill in the art will appreciate that the effective 
amount of any specific compound will vary somewhat from 
compound to compound, and patient to patient, and will 
depend upon the condition of the patient and the route of 
15 delivery. The appropriate dosage for a given subject can be 
determined by methods known in the art. See, e.g., ANSEL'S 
PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS 
(9th Ed., Lippincott Williams and Wilkins (2010)); REMING-
TON'S PHARMACEUTICAL SCIENCES (18th Ed., Maack Publishing 
20 Company, Easton, Pa. (1990)); REMINGTON: THE SCIENCE AND 
PRACTICE OF PHARMAc (21st Ed., Lippincott Williams and 
Wilkins (2005)). In some embodiments, a dosage in a range 
from about 0.1 mg/kg to about 100 mg/kg will have the 
desired effect (e.g., therapeutic efficacy), with all weights 
25 being calculated based upon the weight of the compound, 
including the cases where a salt is employed. More than one 
administration (e.g., two, three, four, five or more adminis-
trations) can be employed at a variety of time intervals (e.g., 
hourly, daily, weekly, monthly, etc.) to achieve the desired 
30 effect(s). 
In some embodiments, a uricase of the present invention 
can be administered to a subject in a dosage range ofabout 0.1 
mg to about 20.0 mg ofuricase every 1-8 weeks (regardless of 
body mass or age). For example, about 5 mg to about 10 mg 
35 ofuricase may be administered to a subject every 2-4 weeks. 
In an exemplary embodiment, about 8 mg ofuricase is admin-
istered to a subject every 2 weeks. 
In some embodiments, a uricase of the present invention 
can be administered to a subject in a dosage range ofabout 0.1 
40 mg per kilogram to about 20.0 mg per kilogram of body 
weight multiple times over the course of several days (e.g., 
3-10 days). For example, about 0.1 to about 1.0 mg ofuricase 
per kilogram of body weight may be administered to a subject 
once a day for 3-10 days. In particular embodiments, about 
45 0.2 mg of uricase per kilogram ofbody weight is administered 
to a subject once a day for 5 days. 
The nucleic acid molecules and vectors of this invention 
can be administered orally, intranasally, parenterally (e.g., 
intravenously), by intramuscular injection, by intraperitoneal 
injection, transdermally, transmucosally, extracorporeally, 
topically or the like. In the methods described herein which 
include the administration and uptake of exogenous nucleic 
acid into the cells of a subject (i.e., gene transduction or 
transfection), the nucleic acid molecules of the present inven-
Methods of treating and/or preventing hyperuricemia, 
gout, tumor lysis syndrome and/or hypertension can com-
prise, consist essentially of or consist of administering to the 50 
subject an effective amount of one or more (unconjugated or 
conjugated) uricases of the present invention, one or more 
nucleic acid molecules of the present invention, one or more 
vectors of the present invention and/or one or more cells of the 
present invention. 55 ti on can be in the form of naked nucleic acid or the nucleic 
acid molecules can be in a vector for delivering the nucleic 
acid molecules to the cells for expression of the polypeptides 
and/or fragments of this invention. In some embodiments, the 
vector can be a commercially available preparation or can be 
constructed in the laboratory according to methods well 
known in the art. In further embodiments, the vector can be a 
viral vector, as is well known in the art. 
In some embodiments, the uricase(s), nucleic acid mol-
ecule(s), vector(s) and/or cell(s) are administered as part of a 
composition comprising the uricase(s), nucleic acid 
molecule(s), vector(s) and/or cell(s) and a pharmaceutically 
acceptable carrier. As described above, such compositions 60 
may comprise any suitable pharmaceutically acceptable car-
rier, stabilizing agent, buffer, diluents, excipient, adjuvant, 
etc. Delivery of the nucleic acid molecule and/or vector of this 
invention to cells can be via a variety of mechanisms that are 
65 well known in the art. As one example, delivery can be via a 
liposome, using commercially available liposome prepara-
tions such as LIPOFECTIN®, LIPOFECTAMINE™ 
Uricases, nucleic acid molecules, vectors and cells of the 
present invention can be administered by any method known 
in the art, including, but not limited to, oral administration, 
parenteral administration (including, but not limited to, sub-
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invention, and not to exhaustively specify all permutations, 
combinations and variations thereof. 
The following non-limiting examples are provided to fur-
ther illustrate the present invention. 
Example 1 
Recombinant Human Uricase 
(GIBCO-BRL, Inc., Gaithersburg, Md.), SUPERFECT® 
(Qiagen, Inc. Hilden, Germany) and TRANSFECTAM® 
(PromegaBiotec, Inc., Madison, Wis.), as well as other lipo-
somes developed according to procedures standard in the art. 
In addition, the nucleic acid molecule and/or vector of this 
invention can be delivered in vivo by electroporation, the 
technology for which is available from Genetronics, Inc. (San 
Diego, Calif.) as well as by means of a SONOPORATION 
machine (ImaRx Pharmaceutical Corp., Tucson, Ariz.). 
Although the human ukase gene contains two stop codons 
(and an aberrant slice-acceptor site), these mutations could 
easily be replaced with sense codons (e.g., the stop codons 
could be replaced with amino acids derived from homologous 
uricase sequences) and the resulting open reading frame, 
15 minus intrans, could serve as a gene for heterologous expres-
sion and purification. The purified human uricase protein 
could then be used for infusion or injection into human sub-
jects. 
In particular embodiments as described herein, vector 10 
delivery can be via a viral system, such as a retroviral vector 
system, which can package a recombinant retroviral genome. 
The recombinant retrovirus can then be used to infect and 
thereby deliver to the infected cells nucleic acid molecules 
encoding the polypeptide and/or fragment of this invention. 
The exact method of introducing the exogenous nucleic acid 
into mammalian cells is, of course, not limited to the use of 
retroviral vectors. Other techniques are widely available for 
this procedure including the use of adenoviral vectors, 20 
alphaviral vectors, adeno-associated viral (AAV) vectors, 
lentiviral vectors, pseudo typed retroviral vectors and vac-
cinia viral vectors, as well as any other viral vectors now 
known or developed in the future. Physical transduction tech-
niques can also be used, such as liposome delivery and recep- 25 
tor-mediated and other endocytosis mechanisms. This inven-
tion can be used in conjunction with any of these or other 
commonly used gene transfer methods. 
The mutational events that resulted in the non-functional 
uricase within the hominoid lineage are predicted to have 
occurred on the order of 15-20 million years ago. If this is the 
case, the human uricase has had millions of years to accumu-
late amino acid replacements due to the loss of selective 
constraints acting on the gene and these replacements may 
have diminished and/or abolished catalytic activity. 
In the present invention, a molecular evolutionary analysis 
has been applied in an attempt to better understand the amino 
acid replacements that have occurred in hominoid uricases as 
well as the selective constraints governing the evolution of 
these hominoid uricase genes. These analyses consisted of 
G-tests to compare the number of synonymous versus non-
As one nonlimiting example, the nucleic acid molecule of 
this invention can be delivered to the cells of a subject in a 30 
modified vaccinia virus vector. The dosage for administration 
of vaccinia-based vectors to humans can typically range from 
about 107 to about 5xl09 plaque forming units (pfu)perinjec-
tion. 
As another nonlimiting example, the nucleic acid molecule 
of this invention can be delivered to the cells of a subject in an 
adenovirus vector. The dosage for administration of adenovi-
rus to humans can range from about 107 to about 1011 pfu per 
injection. 
In some embodiments, a subject will receive a single injec-
tion of a viral vector comprising a nucleic acid molecule of 
this invention. If additional injections are necessary, they can 
be repeated at daily/weekly/monthly intervals for an indefi-
nite period and/or until the efficacy of the treatment has been 
established. As set forth herein, the efficacy of treatment can 
be determined by evaluating the symptoms and clinical 
parameters described herein. 
The exact amount of the nucleic acid molecule and/or 
vector required will vary from subject to subject, depending 
on the species, age, weight and general condition of the sub-
ject, the particular nucleic acid molecule and/or vector used, 
its mode of administration and the like. Thus, it is not possible 
to specify an exact amount for every nucleic acid or vector. 
However, an appropriate amount can be determined by one of 
ordinary skill in the art using only routine experimentation 
given the teachings herein. 
EXAMPLES 
The following examples are not intended to be a detailed 
catalog of all the different ways in which the present invention 
may be implemented or of all the features that may be added 
synonymous substitutions during primate uricase evolution, 
the dN/dS metric to detect positive selection/adaptive evolu-
tion, and mapping amino acid replacements inferred to have 
35 occurred during early primate evolution using homology 
modeling on a three-dimensional uricase structure. These 
analyses provide strong evidence that primate uricases expe-
rienced positive selection early in primate evolution based on 
the large number of nonsynonymous mutations that replaced 
40 amino acids versus a small portion of synonymous mutations 
during the same time period. The results suggest that primate 
uricases accumulated amino acids in a manner that actually 
decreased their enzymatic activity and that there was a selec-
tive advantage for this decreased activity. Such results con-
45 tradict the hypothesis that hominoid uricase has been a 
pseudogene for 15-20 Ma. Mapping the amino acid replace-
ments that occurred during this time period onto a homolo-
gous structure confirmed this. The majority of the amino acid 
replacements occurred in the active site of the protein (data 
50 not shown). This would indicate that ancestral ape primate 
uricases did not encode highly active uricase even before the 
stop codons were introduced into these orthologous genes. 
To confirm that the human uricase gene would not encode 
a highly functional uricase even with the removal of the two 
55 stop internal stop codons, a recombinant human uricase sub-
unit (SEQ ID N0:9) was engineered wherein the two stop 
codons were replaced with arginines and the intrans were 
removed from the gene. The recombinant human uricase was 
cloned into the pET-15b vector (Novagen®, EMD Chemi-
60 cals, Inc., Gibbstown, N.J.) and expressed in Tuner™ (DE3) 
cells (Novagen®, EMD Chemicals, Inc., Gibbstown, N.J.). 
Expression was confirmed via Western blot. Unfortunately, 
the recombinant human uricase resided in the insoluble frac-to the present invention. Persons skilled in the art will appre-
ciate that numerous variations and additions to the various 
embodiments may be made without departing from the 65 
present invention. Hence, the following descriptions are 
intended to illustrate some particular embodiments of the 
tion during purification. Attempts were made to refold the 
recombinant human uricase following solubilization with 
urea or guanidine hydrochloride, but it was not clear whether 
those attempts were successful because no uricolytic activity 
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was detected following the re-folding attempts. It was not 
clear whether the lack of uricolytic activity in the samples was 
the result of a failure to refold the recombinant human uricase 
properly or an inherent lack of uricolytic activity despite 
proper refolding. 
Next, the recombinant human uricase subunit and a pig 
uricase subunit (SEQ ID NO:lO) were each cloned into a 
separate pIRESpuro3 mammalian expression vector (Clon-
Tech, Clontech Laboratories, Inc., Mountain View, Calif.) 
with 5'-EcoRI and 3'-Notl restriction sites and expressed in 
human hepatocytes. Expression of each uricase was con-
firmed with an antibody that recognizes an evolutionarily 
conserved uricase epitope. Uricolytic activity was assessed 
by comparing the effects of the recombinant human uricase 
and pig uricase on several markers ofuricase activity (intra-
cellular uric acid levels, triglyceride levels and fatty acid 
synthase levels) in vivo. Unlike pig uricase, the recombinant 
human uricase possessed no uricolytic activity (data not 
shown). 
Example 2 
Resurrecting Ancient Uricases 
Uricases were designed using Ancestral Sequence Recon-
struction (ASR) to reconstruct and resurrect ancestral forms 
26 
Example 4 
Inclusion Body Preparation and Uricase Extraction 
Frozen cells from Example 3 were thawed at room tem-
perature and resuspended in 4 ml Bugbuster® Protein Extrac-
tion Reagent (Novagen®, EMD Chemicals, Inc., Gibbstown, 
N.J.) containing 4 µl Benzonase® endonuclease (Novagen®, 
EMD Chemicals, Inc., Gibbstown, N.J.). Cells were incu-
10 bated with gentle rocking for 30 min at room temperature. 
Insoluble uricase was pelleted by centrifugation at 16,000xg 
for 20 min at 4 ° C., and the supernatant was discarded. Inclu-
sion bodies were washed overnight in 4 ml of IM Na2C03 , 
pH 10.2 to remove contaminating proteins. Uricase was 
15 extracted from the washed inclusion bodies via a 4 hour 
incubation in 4 ml of 0.5M Na2 C03 , pH 11. Carbonate-
insoluble debris was removed by centrifugation at 20,190xg 
for 30 min at 6° C. The purity of the uricases extracted from 
the cells was confirmed by the presence of a single 35 kDa 
20 band in supernatant samples separated and visualized using 
SDS-PAGE analysis (See, e.g., FIG. 2). The uricolytic activ-
ity of the extracted uricases was confirmed using an Amp lex® 
Red Uricase Assay Kit (Molecular Probes, Inc., Eugene, 
Oreg.). 
25 
Example 5 
of human uricase based upon an analysis of modem mamma-
lian uricases. See generally Gaucher, "Ancestral sequence 30 
reconstruction as a tool to understand natural history and 
guide synthetic biology: Realizing (and extending) the vision 
Purification of Synthetic Uricases 
Tetrameric uricases were separated from octameric 
uricases and larger aggregates in the carbonate extraction 
supernatant at 4 ° C. using an AKTA ™ Design UPC 10 size 
exclusion chromatography system (GE Healthcare Life Sci-
ences, Piscataway, N.J.). The carbonate extraction supema-
tants from Example 2 were centrifuged for 20 min at 
20,000xg to remove any remaining cell debris, then applied 
directly to a HiLoad™ 16/60 Superdex™ 200 prep grade 
column (GE Healthcare Life Sciences, Piscataway, N.J.) pre-
equilibrated with O.lM Na2 C03 , pH 11. Tetrameric uricase 
was eluted at around 65 ml (as monitored by absorbance at 
280 nm; FIG. 3). This peak was collected in 2 ml fractions, 
pooled and concentrated by centrifugation using Pierce Pro-
tein Concentrators (Thermo Fisher Scientific, Inc., Rockford, 
Ill.). 
of Zukerkandl and Pauling" in ANCESTRAL SEQUENCE REcoN-
STRucnoN, ed. David A. Liberles, pp. 20-33 (Oxford Univer-
sity Press, 2007). Ancestral uricase sequences corresponding 35 
to various nodes of the phylogenetic tree were inferred by 
analyzing modern mammalian uricase sequences (FIG. 1), 
and uricases were designed based upon those inferred 
sequences. Uricase subunits of the present invention may 
therefore comprise an amino acid sequence corresponding to 40 
the inferred amino acid sequence at one of the nodes high-
lighted in FIG. 1 (e.g., Node 18, Node 19, Node 26, Node 27, 
Node 30, Node 31 or Node 32) or to a variant of the inferred 
amino acid sequence at one of the nodes highlighted in FIG. 
1. 
Example 3 
Synthetic Uricase Expression 
Nucleic acid sequences encoding various uricase subunits 
of the present invention were each cloned into a pET-21a 
vector (Novagen®, EMD Chemicals, Inc., Gibbstown, N.J.) 
using the amino terminal NdeI and the carboxy-terminal 
XhoI restriction sites. Tuner™ (DE3) cells (Novagen®, EMD 
Chemicals, Inc., Gibbstown, N.J.) were transformed, and a 
single colony was used to inoculate 5 ml of Luria Broth (LB), 
which was incubated overnight at 37° C. Fresh LB (250 mL) 
containing 100 µg/ml carbenicillin and 100 µg/ml chloram-
phenicol was seeded with 2.5 ml of overnight culture. Cells 
were grown to an OD600 between 0.6 and 0.8, and expression 
was induced using a final concentration of 1 mM IPTG. 
Expression was carried out overnight (16-20 hours) at 37° C. 
with shaking at 250 rpm. Cells were collected by centrifuga-
tion at 5,000xg for 30 minutes at 6° C. and stored at -80° C. 
in 50 ml conical tubes. 
45 
Example 6 
Uricolytic Activity of Synthetic Uricases 
50 The uricolytic activities of the uricases collected in 
Example 5 and previously known uricases were determined 
spectrophotometrically by monitoring decreases in absor-
bance at the absorption maxima of uric acid (293 nm; here-
inafter "A293"). Reactions were performed in 1 ml reaction 
55 volumes in quartz cuvettes at 24° C. or 37° C. using the 
following uric acid concentrations: 1 µM, 2.5 µM, 5 µM, 10 
µM, 15 µM, 20 µM, 25 µM, 50 µM, 75 µMand 100 µM. The 
amount of uricase added to each reaction was adjusted to give 
a linear decrease in uric acid over the 6 minute time course of 
60 the assay. The initial velocity of each reaction was determined 
by plotting the decrease inA293 versus time and determining 
the slope in the linear portion of the curve. Each assay was run 
in triplicate, and the average initial velocity of each assay was 
used to plot a hyperbolic regression curve to determine the 
65 Michaelis Constant (KM) and the maximum reaction rate 
(V max) of the corresponding uricase. The concentration of 
uricase in each assay was determined using a Quick Start™ 
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Bradford Assay (Bio-Rad Laboratories, Inc., Hercules, 
Calif.) and used to determine kcat for each uricase. 
The kinetic parameters of several uricases are described in 
Table 3, including pig uricase (each subunit having the amino 
acid sequence of SEQ ID NO:lO), a pig-baboon chimeric 
uricase (the first 225 amino acids of each subunit correspond-
ing to amino acids 1-225 of SEQ ID NO: 10 and the remaining 
79 amino acids of each subunit corresponding to amino acids 
226-304 of SEQ ID NO: 11)), a uricase comprising four iden-
tical uricase subunits having the amino acid sequence of SEQ 
10 ID N0:2 ("Node 19"), a uricase comprising four identical 
uricase subunits having the amino acid sequence of SEQ ID 
N0:3 ("Node 26") and a uricase comprising four identical 
uricase subunits having the amino acid sequence of SEQ ID 
28 
in vivo testing protocols. For example, uricases, uricase sub-
units, nucleic acid molecules, vectors and cells of the present 
invention can be tested in uricase-deficient animals, such as 
Vox+1- or Vox-1- mice (See, e.g., Kelly et al., J. AM. Soc. 
NEPHROL 12:1001-1009 (2001)). 
Example 8 
Reducing Uric Acid Levels in a Human Subject 
As one nonlimiting example of this invention, a human 
subject whose initial uric acid level is at least 6.0 mg/dL in N0:4 ("Node 27"). 
15 blood plasma can be administered a dose of about 5 mg to 
Pig Uricase * a 
Pig-Baboon Uricase *a 
Node 19 *a 
Node 26 **a 
Node 27 **a 
Node 26 ** ~ 
TABLE3 
vmax 
(µmol uric acid/min) 
2.4 x 10-3 
2.8 x 10-3 
4.3 x 10-3 
1.4 x 10-3 
8.1 x 10-4 
4.3 x 10-3 
*in O.lMNa2HP04/Na2H2P04, pH 7.4 
**in phosphate buffered saline, pH 7.4 
a tested at 24° C. 
~tested at 37° C. 
Example 7 
In vivo Testing 
KM kc at 
(µM uric acid) (min-1) 
2.1 470 
2.2 287 
4.0 325 
4.9 75 
5.3 25 
4.9 225 
Uricases, uricase subunits, nucleic acid molecules, vectors 
and cells of the present invention can be tested using various 
<160> NUMBER OF SEQ ID NOS, 11 
<210> SEQ ID NO 1 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
SEQUENCE LISTING 
20 
25 
30 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 1 
about 10 mg (e.g., about 8 mg) of a uricase of the present 
invention (e.g., a uricase comprising four identical uricase 
subunits comprising the amino acid sequence of SEQ ID 
N0:2) via intravenous injection every two weeks for twelve 
weeks. The subject's uric acid level can be monitored over the 
twelve week treatment period, with the treatment goal of 
maintaining the subject's uric acid level at a mean of about 1.0 
mg/dL. 
The above examples clearly illustrate the advantages of the 
invention. Although the present invention has been described 
with reference to specific details of certain embodiments 
thereof, it is not intended that such details should be regarded 
as limitations upon the scope of the invention except as and to 
the extent that they are included in the accompanying claims. 
Throughout this application, various patents, patent publi-
cations and non-patent publications are referenced. The dis-
closures of these patents, patent publications and non-patent 
publications in their entireties are incorporated by reference 
herein into this application in order to more fully describe the 
state of the art to which this invention pertains. 
Met Ala His Tyr His Gly His Leu Thr Lys Asn Ala Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Val Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys His His Ile Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Asn Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Thr Ile Glu Ala Phe Ala Met Asn Ile Gly Lys 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
US 8,940,861 B2 
29 
-continued 
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Asn His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Lys Arg Gly Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Arg Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr Asp Gln Ser Arg Ala Val Asp Phe Glu 
195 200 205 
Ala Ile Trp Asp Thr Val Leu Asp Ile Val Leu Glu Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 2 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 2 
Met Ala His Tyr His Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Ala Met Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Met Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
30 
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-continued 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Val Arg Asp Ile Val Leu Glu Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 3 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 3 
Met Ala His Tyr His Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Ala Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
32 
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-continued 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 4 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 4 
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
34 
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<210> SEQ ID NO 5 
<211> LENGTH, 304 
<212> TYPE, PRT 
35 
<213> ORGANISM, Artificial 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 5 
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Leu Glu Lys Ser Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 6 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
36 
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-continued 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys His Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Leu Glu Lys Ser Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 7 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 7 
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
38 
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Phe Lys Glu Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys His Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Gln Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Lys 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Met Glu Lys Ser Ala Gly 
210 215 220 
Pro Tyr Asp Lys Asp Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Cys 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Ala Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 8 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, Xaa is Asn or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, Xaa is Asp, Asn or His 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, Xaa is Tyr or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (9) .. (9) 
<223> OTHER INFORMATION, Xaa is Lys or Thr 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (12) .. (12) 
<223> OTHER INFORMATION, Xaa is Asp or Ala 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, Xaa is Asp or Glu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, Xaa is Met or Val 
<220> FEATURE, 
40 
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<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (37) .. (37) 
<223> OTHER INFORMATION, Xaa is Tyr or His 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (39) .. (39) 
<223> OTHER INFORMATION, Xaa is Ser or Ile 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (52) .. (52) 
<223> OTHER INFORMATION, Xaa is Ser or Asn 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (83) .. (83) 
<223> OTHER INFORMATION, Xaa is Gly or Glu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, ( 86) .. ( 86) 
<223> OTHER INFORMATION, Xaa is Ser or Thr 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (91) .. (91) 
<223> OTHER INFORMATION, Xaa is Ala or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (92) .. (92) 
<223> OTHER INFORMATION, Xaa is Met or Val 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (95) .. (95) 
<223> OTHER INFORMATION, Xaa is Cys or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (96) .. (96) 
<223> OTHER INFORMATION, Xaa is Glu or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (103) .. (103) 
<223> OTHER INFORMATION, Xaa is Asn or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (112) .. (112) 
<223> OTHER INFORMATION, Xaa is Val or Met 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (115) .. (115) 
<223> OTHER INFORMATION, Xaa is Val or Ile 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (119) .. (119) 
<223> OTHER INFORMATION, Xaa is Arg or His 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (120) .. (120) 
<223> OTHER INFORMATION, Xaa is Phe or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (121) .. (121) 
<223> OTHER INFORMATION, Xaa is Glu or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (126) .. (126) 
<223> OTHER INFORMATION, Xaa is Lys or Asn 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (146) .. (146) 
<223> OTHER INFORMATION, Xaa is Met, Leu or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (147) .. (147) 
<223> OTHER INFORMATION, Xaa is Arg or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (148) .. (148) 
<223> OTHER INFORMATION, Xaa is Ser or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (151) .. (151) 
<223> OTHER INFORMATION, Xaa is Pro or Gln 
US 8,940,861 B2 
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<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (175) .. (175) 
<223> OTHER INFORMATION, Xaa is Lys or Arg 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (177) .. (177) 
<223> OTHER INFORMATION, Xaa is Gln, Arg or Glu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (178) .. (178) 
<223> OTHER INFORMATION, Xaa is Phe or Tyr 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (192) .. (192) 
<223> OTHER INFORMATION, Xaa is Gln or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (200) .. (200) 
<223> OTHER INFORMATION, Xaa is His or Asp 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (202) .. (202) 
<223> OTHER INFORMATION, Xaa is Gly, Cys or Ser 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (204) .. (204) 
<223> OTHER INFORMATION, Xaa is Asp or Ala 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (208) .. (208) 
<223> OTHER INFORMATION, Xaa is Glu or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (210) .. (210) 
<223> OTHER INFORMATION, Xaa is Thr or Ile 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (214) .. (214) 
<223> OTHER INFORMATION, Xaa is Val or Ile 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (215) .. (215) 
<223> OTHER INFORMATION, Xaa is Arg or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (217) .. (217) 
<223> OTHER INFORMATION, Xaa is Ile or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (219) .. (219) 
<223> OTHER INFORMATION, Xaa is Leu or Met 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (220) .. (220) 
<223> OTHER INFORMATION, Xaa is Glu or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (222) .. (222) 
<223> OTHER INFORMATION, Xaa is Phe or Ser 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (229) .. (229) 
<223> OTHER INFORMATION, Xaa is Gly or Asp 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (230) .. (230) 
<223> OTHER INFORMATION, Xaa is Glu or Lys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (232) .. (232) 
<223> OTHER INFORMATION, Xaa is Ser or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (233) .. (233) 
<223> OTHER INFORMATION, Xaa is Pro or Thr 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (240) .. (240) 
45 
<223> OTHER INFORMATION, Xaa is Tyr or Cys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (252) .. (252) 
<223> OTHER INFORMATION, Xaa is Glu or Ala 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (265) .. (265) 
<223> OTHER INFORMATION, Xaa is Tyr or Leu 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (273) .. (273) 
<223> OTHER INFORMATION, Xaa is Met or Gly 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (286) .. (286) 
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<223> OTHER INFORMATION, Xaa is Asp, Ser or Cys 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (303) .. (303) 
<223> OTHER INFORMATION, Xaa is Arg or Lys 
<400> SEQUENCE, 8 
Met Ala His Tyr His Xaa Xaa Xaa Xaa Lys Asn Xaa Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Xaa Xaa Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Xaa His Xaa Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Xaa Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Xaa Ile Lys Xaa Ile Glu Ala Phe Xaa Xaa Asn Ile Xaa Xaa 
85 90 95 
His Phe Leu Ser Ser Phe Xaa His Val Ile Arg Ala Gln Val Tyr Xaa 
100 105 110 
Glu Glu Xaa Pro Trp Lys Xaa Xaa Xaa Lys Asn Gly Val Xaa His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Xaa Xaa Xaa Gly Pro Xaa Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Xaa Asp 
165 170 175 
Xaa Xaa Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Xaa 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr Xaa Gln Xaa Arg Xaa Val Asp Phe Xaa 
195 200 205 
Ala Xaa Trp Asp Thr Xaa Xaa Asp Xaa Val Xaa Xaa Lys Xaa Ala Gly 
210 215 220 
Pro Tyr Asp Lys Xaa Xaa Tyr Xaa Xaa Ser Val Gln Lys Thr Leu Xaa 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Xaa Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Xaa Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Xaa Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Xaa Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Xaa Leu 
46 
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<210> SEQ ID NO 9 
<211> LENGTH, 304 
<212> TYPE, PRT 
47 
295 
<213> ORGANISM, Artificial 
<220> FEATURE, 
-continued 
300 
<223> OTHER INFORMATION, Synthetic uricase sequence 
<400> SEQUENCE, 9 
Met Ala His Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Glu Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Glu Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Met 
100 105 110 
Glu Glu Ile Pro Trp Lys His Leu Gly Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Gln Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Lys 
195 200 205 
Ala Thr Trp Asp Thr Ile Arg Asp Leu Val Met Glu Lys Ser Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Leu Thr Ser Val Gln Lys Thr Leu Cys 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Ala Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 10 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Sus scrofa 
<400> SEQUENCE, 10 
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 
1 5 10 15 
48 
US 8,940,861 B2 
49 
-continued 
Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu 
85 90 95 
His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu 
290 295 300 
<210> SEQ ID NO 11 
<211> LENGTH, 304 
<212> TYPE, PRT 
<213> ORGANISM, Papio hamadryas 
<400> SEQUENCE, 11 
Met Ala Asp Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe 
1 5 10 15 
Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 
20 25 30 
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 
35 40 45 
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 
50 55 60 
Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 
65 70 75 80 
Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 
50 
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85 90 95 
Tyr Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 
100 105 110 
Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 
115 120 125 
His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 
130 135 140 
Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 
145 150 155 160 
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 
165 170 175 
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 
180 185 190 
Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 
195 200 205 
Ala Thr Trp Gly Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly 
210 215 220 
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 
225 230 235 240 
Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 
245 250 255 
Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 
260 265 270 
Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 
275 280 285 
Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 
290 295 300 
52 
That which is claimed: 
1. A uricase comprising at least one uricase subunit com-
prising the amino acid sequence of SEQ ID NO:S, whereinX1 40 is N; X2 is D; X3 isY; X4 is K; X5 is D; X6 is D; X7 is M; X8 
Y; X48 is E; X49 is Y; X50 is M; X51 is D; andX52 is Rand said 
uricase has enhanced uricolytic activity relative to a control 
unease. 
is Y; X9 is S; X10 is S; X11 is G; X12 is S; X13 is A; X14 is M; 
X15 is C; X16 is E; X17 is N; X18 is V; X19 is V; X20 is R; X21 
is F; X22 is E: X23 is K; X24 is M; X25 is R; X26 is S; X27 is P; 
X28 is K; X29 is Q; X30 to is F; X31 is Q; X32 is H; X33 is G; X34 45 
is D; X35 is E; X36 is T; X37 is V; X38 is R; X40 is L; X41 is L; 
X41 is E; X42 is F; X43 is G; X44 is E; X45 is S; X46 is P; X47 is 
2. The uricase of claim 1, wherein the uricase is a homotet-
ramer or a homooctamer. 
3. Theuricase of claim 1, wherein theuricase is conjugated 
to one or more oligomers. 
4. A composition comprising the uricase of claim 1, in a 
pharmaceutically acceptable carrier. 
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